NeuroQure Acquires Patents to Detect Autism in Newborns with a Skin Sample
13 déc. 2023 09h30 HE
|
NeuroQure
IRVINE, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- NeuroQure, a pioneering biotech startup specializing in gene therapy for neurocognitive disorders, has reached a pivotal milestone in the...
Autism Spectrum Disorder Treatment Market Size to Surpass USD 13.14 Billion by 2030, exhibiting a CAGR of 8.5%
27 nov. 2023 06h14 HE
|
Fortune Business Insights
Pune, India, Nov. 27, 2023 (GLOBE NEWSWIRE) -- The autism spectrum disorder treatment market size was valued at USD 6.94 billion in 2022, and it is anticipated to expand from USD 7.41 billion in...
Study: Autistic Children May Need Fewer Hours of Treatment Than Previously Thought
21 nov. 2023 13h41 HE
|
Catalight
Walnut Creek, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Each year, tens of thousands of parents and caregivers of children with autism spectrum disorder (ASD) face vital decisions: What kind of...
Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder
20 nov. 2023 08h05 HE
|
Yamo Pharmaceuticals
Yamo Pharmaceuticals LLC has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents with autism spectrum disorder (ASD).
Revolutionizing Care: NeuroQure’s Groundbreaking Path to Treating Genetic Intellectual Disabilities
06 nov. 2023 12h00 HE
|
NeuroQure
IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroQure has embarked on a transformative journey aimed at revolutionizing the treatment landscape for Fragile X Syndrome and Autism Spectrum...
PaxMedica Announces 1-for-17 Reverse Stock Split
30 oct. 2023 11h30 HE
|
PaxMedica, Inc.
TARRYTOWN, N.Y. , Oct. 30, 2023 (GLOBE NEWSWIRE) -- via IBN — PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug...
PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication
26 oct. 2023 13h51 HE
|
PaxMedica, Inc.
TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General...
Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004 for Irritability Associated with Autism
26 sept. 2023 08h00 HE
|
Axial Therapeutics
– Topline clinical data anticipated in 1Q 2024 – – First-in-class small molecule therapeutic targets the microbiome gut-brain axis and its role in autism, offering a potential alternative to...
Autism Spectrum Disorder Therapeutics Market Size to Surpass USD 3.42 Billion by 2030, exhibiting a CAGR of 7.9%
31 août 2023 07h24 HE
|
Fortune Business Insights
Pune, India, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The global autism spectrum disorder therapeutics market size was valued at USD 1.93 billion in 2022 and it is projected to grow from USD 2.01 billion...
DisruptABA™ Virtual Conference: Pursuing Radical Honesty and Change in Applied Behavior Analysis
02 août 2023 09h00 HE
|
Verbal Beginnings
COLUMBIA, Md., Aug. 02, 2023 (GLOBE NEWSWIRE) -- The Applied Behavior Analysis (ABA) professional community is eagerly anticipating the groundbreaking virtual conference, DisruptABA™, which is set...